Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: a retrospective cohort study

[1]  T. Butt,et al.  Ribavirin and Interferon-α2b as Primary and Preventive Treatment for Middle East Respiratory Syndrome Coronavirus: A Preliminary Report of Two Cases , 2014, Antiviral therapy.

[2]  Julie Dyall,et al.  Repurposing of Clinically Developed Drugs for Treatment of Middle East Respiratory Syndrome Coronavirus Infection , 2014, Antimicrobial Agents and Chemotherapy.

[3]  Jihad Ghandour,et al.  Middle East Respiratory Syndrome Coronavirus: A Case-Control Study of Hospitalized Patients , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[4]  A. Arifi,et al.  Clinical Course and Outcomes of Critically Ill Patients With Middle East Respiratory Syndrome Coronavirus Infection , 2014, Annals of Internal Medicine.

[5]  G. Olinger,et al.  Interferon-β and mycophenolic acid are potent inhibitors of Middle East respiratory syndrome coronavirus in cell-based assays. , 2014, The Journal of general virology.

[6]  Z. Memish,et al.  Ribavirin and interferon therapy in patients infected with the Middle East respiratory syndrome coronavirus: an observational study , 2014, International Journal of Infectious Diseases.

[7]  K. To,et al.  Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus , 2013, Journal of Infection.

[8]  M. Katze,et al.  Treatment with interferon-α2b and ribavirin improves outcome in MERS-CoV–infected rhesus macaques , 2013, Nature Medicine.

[9]  Z. Memish,et al.  Therapeutic Options for Middle East Respiratory Syndrome Coronavirus (MERS-CoV) – possible lessons from a systematic review of SARS-CoV therapy , 2013, International Journal of Infectious Diseases.

[10]  Z. Memish,et al.  A family cluster of Middle East Respiratory Syndrome Coronavirus infections related to a likely unrecognized asymptomatic or mild case , 2013, International Journal of Infectious Diseases.

[11]  T. Bestebroer,et al.  MERS-coronavirus replication induces severe in vitro cytopathology and is strongly inhibited by cyclosporin A or interferon-α treatment , 2013, The Journal of general virology.

[12]  D. Cummings,et al.  Hospital outbreak of Middle East respiratory syndrome coronavirus. , 2013, The New England journal of medicine.

[13]  Z. Memish,et al.  Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study , 2013, The Lancet Infectious Diseases.

[14]  H. Feldmann,et al.  Inhibition of novel β coronavirus replication by a combination of interferon-α2b and ribavirin , 2013, Scientific Reports.

[15]  Z. Memish,et al.  Applying lessons from SARS to a newly identified coronavirus , 2013, The Lancet Infectious Diseases.

[16]  C. Sprung,et al.  Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock, 2012 , 2013, Intensive Care Medicine.

[17]  T. Wolff,et al.  Assays for laboratory confirmation of novel human coronavirus (hCoV-EMC) infections. , 2012, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[18]  A. Osterhaus,et al.  Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. , 2012, The New England journal of medicine.

[19]  Paul Garner,et al.  SARS: Systematic Review of Treatment Effects , 2006, PLoS medicine.

[20]  V. Wong,et al.  Severe acute respiratory syndrome: report of treatment and outcome after a major outbreak , 2004, Thorax.

[21]  Elizabeth J Phillips,et al.  Common Adverse Events Associated with the Use of Ribavirin for Severe Acute Respiratory Syndrome in Canada , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[22]  Gail,et al.  International Severe Acute Respiratory and emerging Infections Consortium Partners^ , 2016 .

[23]  R. Evans.  European Centre for Disease Prevention and Control. , 2014, Nursing standard (Royal College of Nursing (Great Britain) : 1987).

[24]  G. Olinger,et al.  Repurposing of clinically developed drugs for treatment of Middle East Respiratory Coronavirus 1 Infection , 2014 .

[25]  J. Sung,et al.  Title The Severe Acute Respiratory Syndrome , 2003 .